Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
69 shown of 5,917 total abstracts
  1. Abstract 14662026-06-03 · 16:00 CT · S406
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    J. Cortes, S. Antonia · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  2. Abstract 11002026-06-05 · 21:15 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    C. Robert, S. Peters, H. Rugo, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  3. Abstract 16562026-06-03 · 20:45 CT · Hall B1
    OlympiA-453: Lynparza (olaparib) adjuvant in HR+ breast cancer
    N. Rizvi, M. Reck, M.C. Garassino, et al. · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  4. Abstract 11682026-06-02 · 13:45 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-393 study)
    H. Borghaei, M. Reck, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  5. Abstract 16462026-06-03 · 15:45 CT · E450
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    P. Schmid, H. Borghaei, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  6. Abstract 12702026-06-05 · 21:45 CT · Hall B1
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    J. Brahmer, S. Modi · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  7. Abstract 18302026-06-02 · 20:15 CT · Hall B1
    Long-term follow-up of Enhertu 3L+ for HR+ breast cancer: DESTINY-Breast-970
    E. Winer, C. Saura, S. Modi, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  8. Abstract 12012026-06-04 · 19:00 CT · S406
    Quality of life outcomes with Tecentriq in patients with TNBC
    R. Herbst, S. Tolaney, C. Saura, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  9. Abstract 17982026-06-05 · 19:15 CT · S406
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    S. Peters, M.C. Garassino, H. Borghaei, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  10. Abstract 17792026-06-01 · 14:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-82 study)
    F. Andre, S. Modi, R. Herbst · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  11. Abstract 13042026-06-03 · 15:30 CT · S100A
    ASCENT-788: Trodelvy (sacituzumab govitecan) adjuvant in TNBC
    C. Robert, S. Tolaney, G. Curigliano · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  12. Abstract 13772026-06-04 · 15:30 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-630 study)
    J. Cortes, L. Paz-Ares, S. Tolaney, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  13. Abstract 19472026-06-04 · 13:30 CT · E450
    Quality of life outcomes with Trodelvy in patients with TNBC
    H. Borghaei, H. Rugo · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  14. Abstract 13042026-06-01 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-234 study)
    E. Winer, J. Cortes · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  15. Abstract 11292026-06-01 · 20:45 CT · S100A
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-184
    S. Tolaney, E. Winer, J. Cortes, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  16. Abstract 15122026-06-05 · 20:45 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-63
    S. Peters, M. Reck, M.C. Garassino · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  17. Abstract 12422026-06-01 · 16:30 CT · E450
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    H. Rugo, N. Rizvi, R. Herbst · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  18. Abstract 18652026-06-05 · 21:45 CT · S100A
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-630
    S. Antonia, S. Peters, E. Winer · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  19. Abstract 17032026-06-04 · 20:15 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-138
    M. Reck, E. Winer, A. Spira, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  20. Abstract 15362026-06-01 · 20:30 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-536 study)
    J. Cortes, P. Schmid, J. Brahmer, et al. · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  21. Abstract 16722026-06-05 · 20:30 CT · S100A
    Long-term follow-up of Tecentriq 3L+ for TNBC: IMpower-566
    N. Rizvi, T. Mok · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  22. Abstract 14422026-06-03 · 15:30 CT · S406
    Long-term follow-up of Tecentriq neoadjuvant for TNBC: IMpower-462
    M. Reck, R. Herbst, A. Spira · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  23. Abstract 12982026-06-01 · 18:00 CT · E450
    PALOMA-959: Ibrance (palbociclib) maintenance in HR+ breast cancer
    P. Schmid, L. Paz-Ares · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  24. Abstract 13232026-06-01 · 16:00 CT · S406
    MONALEESA-971: Kisqali (ribociclib) 2L in HR+ breast cancer
    A. Spira, H. Borghaei, M.C. Garassino · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  25. Abstract 12682026-06-01 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 1L for HR+ breast cancer: OlympiA-306
    P. Schmid, G. Curigliano · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  26. Abstract 13062026-06-02 · 14:45 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-984
    T. Mok, H. Borghaei · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  27. Abstract 15172026-06-02 · 16:30 CT · S406
    Long-term follow-up of Lynparza adjuvant for HR+ breast cancer: OlympiA-722
    J. Cortes, S. Modi, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  28. Abstract 14132026-06-05 · 18:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-995
    N. Rizvi, C. Robert · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  29. Abstract 15712026-06-04 · 20:45 CT · E450
    PALOMA-674: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    S. Modi, S. Tolaney, L. Paz-Ares, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  30. Abstract 19952026-06-04 · 16:15 CT · Hall B1
    PALOMA-965: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    R. Herbst, C. Saura, T. Mok · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  31. Abstract 10662026-06-05 · 19:45 CT · E450
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-129 study)
    G. Curigliano, N. Rizvi · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  32. Abstract 14332026-06-05 · 13:30 CT · Hall B1
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    M.C. Garassino, R. Herbst · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  33. Abstract 19972026-06-01 · 20:00 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-237 study)
    S. Peters, H. Rugo · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  34. Abstract 17102026-06-01 · 21:45 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-493
    F. Andre, M. Reck, T. Mok, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  35. Abstract 17152026-06-01 · 21:15 CT · S100A
    MONARCH-99: Verzenio (abemaciclib) 1L in HR+ breast cancer
    S. Modi, S. Antonia, J. Brahmer, et al. · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  36. Abstract 12192026-06-04 · 14:15 CT · Hall B1
    Long-term follow-up of Keytruda 1L for TNBC: KEYNOTE-208
    G. Curigliano, H. Rugo, S. Antonia, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  37. Abstract 19572026-06-03 · 16:15 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-911
    M.C. Garassino, S. Tolaney · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  38. Abstract 12492026-06-05 · 16:30 CT · E450
    Long-term follow-up of Enhertu adjuvant for HR+ breast cancer: DESTINY-Breast-903
    S. Modi, F. Andre, C. Saura, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  39. Abstract 12032026-06-02 · 19:00 CT · S406
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    S. Peters, S. Tolaney, M.C. Garassino · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  40. Abstract 11862026-06-04 · 13:45 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-703
    R. Herbst, F. Andre, M. Reck, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  41. Abstract 12812026-06-03 · 15:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-599
    H. Borghaei, C. Saura · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  42. Abstract 18442026-06-04 · 20:15 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-110 study)
    H. Rugo, G. Curigliano, S. Tolaney, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  43. Abstract 12142026-06-03 · 16:30 CT · Hall B1
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-134
    S. Antonia, C. Robert · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  44. Abstract 10472026-06-05 · 18:30 CT · E450
    Long-term follow-up of Tecentriq neoadjuvant for TNBC: IMpower-566
    H. Borghaei, G. Curigliano, S. Antonia · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  45. Abstract 10002026-06-02 · 13:30 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-344 study)
    M. Reck, H. Rugo, C. Robert, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  46. Abstract 16122026-06-02 · 15:30 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-385
    T. Mok, C. Robert · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  47. Abstract 15592026-06-03 · 21:15 CT · Arie Crown Theater
    Long-term follow-up of Enhertu maintenance for HR+ breast cancer: DESTINY-Breast-784
    J. Brahmer, G. Curigliano · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  48. Abstract 13072026-06-05 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-916 study)
    S. Peters, A. Spira, N. Rizvi · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  49. Abstract 18532026-06-02 · 20:00 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-165
    S. Tolaney, J. Cortes, G. Curigliano, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  50. Abstract 16092026-06-01 · 20:00 CT · S100A
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-517
    H. Rugo, S. Antonia, C. Saura · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  51. Abstract 10012026-06-04 · 21:30 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with TNBC
    S. Antonia, N. Rizvi, H. Rugo, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  52. Abstract 11452026-06-05 · 14:45 CT · Hall B1
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-881
    T. Mok, S. Tolaney, C. Saura, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  53. Abstract 10142026-06-01 · 18:30 CT · E450
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-64
    S. Peters, H. Borghaei, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  54. Abstract 16972026-06-01 · 19:00 CT · E450
    PALOMA-399: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    L. Paz-Ares, A. Spira, S. Modi · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  55. Abstract 17762026-06-02 · 18:30 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-671
    M.C. Garassino, A. Spira, J. Brahmer, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  56. Abstract 19772026-06-02 · 13:30 CT · S406
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-754
    R. Herbst, A. Spira · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  57. Abstract 19832026-06-01 · 16:45 CT · S100A
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-479
    T. Mok, G. Curigliano, H. Borghaei · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  58. Abstract 10392026-06-04 · 20:15 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-476
    M. Reck, S. Peters, C. Robert, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  59. Abstract 10282026-06-01 · 19:15 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-4 study)
    C. Saura, J. Cortes · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  60. Abstract 10712026-06-04 · 19:45 CT · Arie Crown Theater
    OlympiA-950: Lynparza (olaparib) 2L in HR+ breast cancer
    G. Curigliano, S. Antonia, C. Saura, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  61. Abstract 12732026-06-05 · 16:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-688
    N. Rizvi, S. Peters, J. Cortes · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  62. Abstract 12652026-06-03 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-217 study)
    H. Borghaei, M. Reck, S. Modi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  63. Abstract 11812026-06-04 · 20:15 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-606
    T. Mok, L. Paz-Ares, N. Rizvi · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  64. Abstract 16382026-06-01 · 19:00 CT · S406
    IMpower-263: Tecentriq (atezolizumab) 2L in TNBC
    S. Antonia, N. Rizvi, C. Robert · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  65. Abstract 13022026-06-01 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-740
    G. Curigliano, T. Mok, H. Borghaei, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  66. Abstract 19042026-06-03 · 19:00 CT · S100A
    MONARCH-536: Verzenio (abemaciclib) 1L in HR+ breast cancer
    G. Curigliano, S. Peters · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  67. Abstract 18752026-06-05 · 13:30 CT · S100A
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-478
    G. Curigliano, J. Cortes · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  68. Abstract 13002026-06-01 · 19:30 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-997
    J. Cortes, J. Brahmer, S. Antonia · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  69. Abstract 18742026-06-05 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-73
    H. Borghaei, C. Robert, S. Peters, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.